|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR45B |
Gene summary for WDR45B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR45B | Gene ID | 56270 |
| Gene name | WD repeat domain 45B | |
| Gene Alias | NEDSBAS | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000045 | UniProtAcc | A0A024R8U4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56270 | WDR45B | GSM4909282 | Human | Breast | IDC | 2.26e-07 | 4.22e-01 | -0.0288 |
| 56270 | WDR45B | GSM4909293 | Human | Breast | IDC | 1.96e-04 | 2.79e-01 | 0.1581 |
| 56270 | WDR45B | GSM4909294 | Human | Breast | IDC | 4.04e-03 | -1.93e-01 | 0.2022 |
| 56270 | WDR45B | GSM4909296 | Human | Breast | IDC | 6.07e-15 | -3.46e-01 | 0.1524 |
| 56270 | WDR45B | GSM4909297 | Human | Breast | IDC | 1.18e-12 | -2.87e-01 | 0.1517 |
| 56270 | WDR45B | GSM4909309 | Human | Breast | IDC | 1.90e-02 | -2.08e-01 | 0.0483 |
| 56270 | WDR45B | GSM4909311 | Human | Breast | IDC | 7.33e-25 | -3.30e-01 | 0.1534 |
| 56270 | WDR45B | GSM4909312 | Human | Breast | IDC | 3.77e-13 | -2.24e-01 | 0.1552 |
| 56270 | WDR45B | GSM4909319 | Human | Breast | IDC | 6.62e-29 | -2.86e-01 | 0.1563 |
| 56270 | WDR45B | GSM4909320 | Human | Breast | IDC | 4.19e-09 | 2.37e-01 | 0.1575 |
| 56270 | WDR45B | GSM4909321 | Human | Breast | IDC | 4.94e-10 | -5.86e-02 | 0.1559 |
| 56270 | WDR45B | ctrl6 | Human | Breast | Precancer | 1.30e-05 | 5.05e-01 | -0.0061 |
| 56270 | WDR45B | brca3 | Human | Breast | Precancer | 6.01e-03 | 3.23e-01 | -0.0263 |
| 56270 | WDR45B | NCCBC14 | Human | Breast | DCIS | 4.77e-06 | -1.96e-01 | 0.2021 |
| 56270 | WDR45B | NCCBC3 | Human | Breast | DCIS | 3.93e-05 | -2.06e-01 | 0.1198 |
| 56270 | WDR45B | NCCBC5 | Human | Breast | DCIS | 1.28e-11 | -1.61e-01 | 0.2046 |
| 56270 | WDR45B | P1 | Human | Breast | IDC | 4.96e-17 | -2.97e-01 | 0.1527 |
| 56270 | WDR45B | P2 | Human | Breast | IDC | 8.96e-09 | 4.39e-01 | 0.21 |
| 56270 | WDR45B | DCIS2 | Human | Breast | DCIS | 8.48e-46 | 1.45e-01 | 0.0085 |
| 56270 | WDR45B | LZE2T | Human | Esophagus | ESCC | 2.23e-03 | 4.72e-01 | 0.082 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001623610 | Oral cavity | OSCC | macroautophagy | 192/7305 | 291/18723 | 7.01e-21 | 1.14e-18 | 192 |
| GO:19030088 | Oral cavity | OSCC | organelle disassembly | 85/7305 | 114/18723 | 1.15e-14 | 6.93e-13 | 85 |
| GO:007149620 | Oral cavity | OSCC | cellular response to external stimulus | 186/7305 | 320/18723 | 2.56e-12 | 1.05e-10 | 186 |
| GO:00070335 | Oral cavity | OSCC | vacuole organization | 115/7305 | 180/18723 | 1.11e-11 | 4.00e-10 | 115 |
| GO:000042210 | Oral cavity | OSCC | autophagy of mitochondrion | 59/7305 | 81/18723 | 6.40e-10 | 1.63e-08 | 59 |
| GO:006172610 | Oral cavity | OSCC | mitochondrion disassembly | 59/7305 | 81/18723 | 6.40e-10 | 1.63e-08 | 59 |
| GO:003166819 | Oral cavity | OSCC | cellular response to extracellular stimulus | 141/7305 | 246/18723 | 3.99e-09 | 8.95e-08 | 141 |
| GO:003166720 | Oral cavity | OSCC | response to nutrient levels | 245/7305 | 474/18723 | 1.02e-08 | 2.10e-07 | 245 |
| GO:003166918 | Oral cavity | OSCC | cellular response to nutrient levels | 121/7305 | 215/18723 | 1.96e-07 | 3.17e-06 | 121 |
| GO:004259416 | Oral cavity | OSCC | response to starvation | 111/7305 | 197/18723 | 5.68e-07 | 8.19e-06 | 111 |
| GO:000926717 | Oral cavity | OSCC | cellular response to starvation | 91/7305 | 156/18723 | 7.55e-07 | 1.06e-05 | 91 |
| GO:19050374 | Oral cavity | OSCC | autophagosome organization | 63/7305 | 103/18723 | 4.30e-06 | 4.98e-05 | 63 |
| GO:00000454 | Oral cavity | OSCC | autophagosome assembly | 60/7305 | 99/18723 | 1.09e-05 | 1.14e-04 | 60 |
| GO:00421572 | Oral cavity | OSCC | lipoprotein metabolic process | 77/7305 | 135/18723 | 1.61e-05 | 1.60e-04 | 77 |
| GO:00064972 | Oral cavity | OSCC | protein lipidation | 56/7305 | 92/18723 | 1.77e-05 | 1.72e-04 | 56 |
| GO:00421582 | Oral cavity | OSCC | lipoprotein biosynthetic process | 57/7305 | 96/18723 | 4.17e-05 | 3.61e-04 | 57 |
| GO:00448042 | Oral cavity | OSCC | autophagy of nucleus | 12/7305 | 16/18723 | 3.83e-03 | 1.57e-02 | 12 |
| GO:001623615 | Oral cavity | LP | macroautophagy | 135/4623 | 291/18723 | 4.71e-16 | 6.70e-14 | 135 |
| GO:0022411110 | Oral cavity | LP | cellular component disassembly | 173/4623 | 443/18723 | 9.97e-12 | 7.44e-10 | 173 |
| GO:190300815 | Oral cavity | LP | organelle disassembly | 60/4623 | 114/18723 | 1.28e-10 | 7.30e-09 | 60 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR45B | SNV | Missense_Mutation | c.923T>G | p.Val308Gly | p.V308G | Q5MNZ6 | protein_coding | deleterious(0) | possibly_damaging(0.832) | TCGA-A1-A0SO-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | SD | ||
| WDR45B | SNV | Missense_Mutation | novel | c.734T>A | p.Ile245Asn | p.I245N | Q5MNZ6 | protein_coding | deleterious(0) | benign(0.24) | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| WDR45B | insertion | Nonsense_Mutation | novel | c.777_778insTCTTAACCCTGTAGCCAACACCGGGTGATTAGATGCTCACCCCAAGACCGTCA | p.Glu260SerfsTer2 | p.E260Sfs*2 | Q5MNZ6 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| WDR45B | insertion | Frame_Shift_Ins | novel | c.731_732insACTACAAATTCCTGTT | p.Ile245LeufsTer21 | p.I245Lfs*21 | Q5MNZ6 | protein_coding | TCGA-BH-A0BM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | ||
| WDR45B | SNV | Missense_Mutation | novel | c.866N>G | p.Phe289Cys | p.F289C | Q5MNZ6 | protein_coding | deleterious(0) | possibly_damaging(0.818) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WDR45B | SNV | Missense_Mutation | novel | c.322N>T | p.Arg108Trp | p.R108W | Q5MNZ6 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| WDR45B | SNV | Missense_Mutation | c.77N>T | p.Ala26Val | p.A26V | Q5MNZ6 | protein_coding | deleterious(0.04) | benign(0.092) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| WDR45B | SNV | Missense_Mutation | rs780142007 | c.1024G>A | p.Asp342Asn | p.D342N | Q5MNZ6 | protein_coding | deleterious(0.04) | benign(0.017) | TCGA-C5-A2LX-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| WDR45B | SNV | Missense_Mutation | c.249N>A | p.Met83Ile | p.M83I | Q5MNZ6 | protein_coding | tolerated(0.23) | benign(0) | TCGA-EA-A3HR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| WDR45B | SNV | Missense_Mutation | novel | c.887N>T | p.Pro296Leu | p.P296L | Q5MNZ6 | protein_coding | tolerated(0.05) | benign(0.084) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |